Monday, June 22, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 714 of 1,261
  1. US 9234000

    Benzylamine derivatives as inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  2. US 9233973

    Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  3. US 9233932

    Oligomer-nitroimidazole anti-infective conjugates

    Nektar Therapeutics · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  4. US 9233927

    Crystals of laquinimod sodium and improved process for the manufacture thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  5. US 9233170

    Interfering RNA delivery system and uses thereof

    Arrowhead Research Corporation · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  6. US 9233169

    Oligomer-bis-chromonyl compound conjugates

    Nektar Therapeutics · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  7. US 9233164

    Water soluble fullerene formulations and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  8. US 9233162

    High affinity VEGF-receptor antagonists

    The Board of Regents of the University of Texas System · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  9. US 9233131

    Mutant adeno-associated virus virions and methods of use thereof

    The Regents of the University of California · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  10. US 9233121

    Compositions and methods for the treatment of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  11. US 9233165

    Oligomer-aryloxy-substituted propanamine conjugates

    Nektar Therapeutics · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  12. US 9233167

    Oligomer-opioid agonist conjugates

    Nektar Therapeutics · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  13. US 9233095

    Small molecule RNase inhibitors and methods of use

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  14. US 9233085

    Topical application of AMPK activators for pharmacological prevention of chronic pain

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  15. US 9233103

    Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy

    Takeda Pharmaceuticals U.S.A., Inc. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  16. AU 2014283378

    2,3-dihydrobenzofuran-5-yl compounds as DYRK kinase inhibitors

    4SC DISCOVERY GMBH [DE] · Granted Jan 7, 2016 · Expires Jan 2, 2036

    granted
  17. WO 2016001312

    DISPOSITIF POUR LA FABRICATION DE TIMBRES PHARMACEUTIQUES

    ACINO AG [DE] · Granted Jan 7, 2016 · Expires Jan 2, 2036

    granted
  18. EP 2961422

    THERAPEUTIKUM FÜR FRUCHTWASSEREMBOLIE

    CSL BEHRING GMBH [DE] · Granted Jan 6, 2016 · Expires Jan 1, 2036

    granted
  19. US 9228014

    Antibodies capable of blocking the interaction between CD48 and a CD48 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  20. US 9226921

    Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  21. US 9228172

    Inducible regulatory T-cell generation for hematopoietic transplants

    Regents of the University of Minnesota · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  22. US 9226881

    Multi-functional composite powder

    JGC Catalysts and Chemicals Ltd. · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  23. US 9226970

    Oligomer modified diaromatic substituted compounds

    Nektar Therapeutics · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  24. US 9228171

    Regulatory B cells (tBREGS) and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.